The cost effectiveness and budget impact of natalizumab for formulary inclusion

References

• Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008;71:(24 Suppl 3):S3–7
   Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–911
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390–407
   PubMedGoogle Scholar
• Loftus EV Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002;16:51–60
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641–1657
   PubMed Web of Science ®Google Scholar
• Gasche C, Scholmerich J, Brynskov J, A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8–15
   PubMed Web of Science ®Google Scholar
• Yu AP, Cabanilla LA, Wu EQ, The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24:319–328
   PubMed Web of Science ®Google Scholar
• Taylor B, Mcdonald E, Fantino B, The cost of multiple sclerosis in Australia. J Clin Neurosci 2007;14:532–539
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918–926
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571–580
   PubMedGoogle Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655–661
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285–294
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498–1504
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268–1276
   PubMed Web of Science ®Google Scholar
• 2008 Physicians' Fee and Coding Guide. MAG Mutual Healthcare Solutions, Inc. Duluth, GA, 2008
   Google Scholar
• TYSABRI (natalizumab) [package insert]. Cambridge, MA: Biogen Idec, Inc., 2008
   Google Scholar
• Betaseron (interferon beta-1b) [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals, 2007
   Google Scholar
• Copaxone (glatiramer acetate) [package insert]. Kansas City, MO: Teva Neuroscience, Inc., 2007
   Google Scholar
• Rebif (interferon beta-1a) [package insert]. Rockland, MA: Serono, Inc., 2008
   Google Scholar
• Avonex (interferon beta-1a) [package insert]. Cambridge, MA: Biogen Idec, Inc., 2006
   Google Scholar
• Hermann BP, Vickrey B, Hays RD, A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996;25:113–118
   PubMed Web of Science ®Google Scholar
• O'brien JA, Ward AJ, Patrick AR, Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17
   PubMed Web of Science ®Google Scholar
• EVIDENCE trial. US Food and Drug Administration Supplemental Biologics License Application
   Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549
   PubMed Web of Science ®Google Scholar
• Remicade [prescribing information]. Malvern, PA: Centocor Inc.; April 2007. http://www.remicade.com/remicade/assets/HCP_PPI.pdf. [Accessed January 14, 2008]
   Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912–1925
   PubMed Web of Science ®Google Scholar
• Humira [prescribing information]. North Chicago, IL: Abbott Laboratories; July 2007. http://www.rxabbott.com/pdf/humira.pdf. [Accessed January 14, 2008]
   Google Scholar
• Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 2005;91:302–308
   Google Scholar
• Tysabri (natalizumab) in Multiple Sclerosis Dossier. Biogen Idec, Inc., and Elan Pharmaceuticals, Inc., October 2008
   Google Scholar
• Tysabri (natalizumab) in Crohn's Disease Dossier. Biogen Idec, Inc., and Elan Pharmaceuticals, Inc., April 2008
   Google Scholar
• Dong X, Fetterolf D. Specialty pharmacy: an emerging area of interest for medical management. Dis Manage 2005;8:73–85
   PubMedGoogle Scholar